Clinical Trial to Evaluate the Efficacy and Safety of Sarpogrelate SR in Patients With Chronic Artery Occlusive Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

148 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-11-18

Study Completion Date

2023-03-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This clinical trial aims to assess the non-inferiority of Sarpogrelate SR 300mg once daily compared to Sarpogrelate 100mg three times daily in patients having intermittent claudication among chronic artery occlusive disease, based on changes in the Ankle-Brachial Index (ABI).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Multicenter, Therapeutic Use Observational Study to Evaluate the Effects of Concurrent Therapy of Sarpogrelate

NCT05083299

Chronic Occlusive Arterial Disease

COMPLETED

Clinical Trial to Evaluate Efficacy and Safety of DP-R202 and Anplag in Patients With Artery Occlusive Disease

NCT02393612

Peripheral Arterial Disease

COMPLETED PHASE3

Study of Prasugrel in Korean Healthy Male Volunteers

NCT01591317

Healthy Volunteers

COMPLETED PHASE1

Impact of Sarpogrelate in the Function of Endothelial Progenitor Cells

NCT01548274

Atherosclerosis

UNKNOWN NA

Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Subjects With Stable Coronary Artery Disease

NCT01587651

Coronary Artery Disease

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The clinical trial is a randomized, multicenter, open-label, parallel-group, Phase 4 study conducted to evaluate the non-inferiority of Sarpogrelate SR 300mg once daily compared to Sarpogrelate 100mg three times daily in patients having intermittent claudication among chronic artery occlusive disease. Eligible patients who sign the informed consent form voluntarily will receive the investigational products. Subsequently, they will undergo observation and various assessments at the 12-week and 24-week visits. The trial is designed to determine whether Sarpogrelate SR 300mg once daily is inferior to Sarpogrelate 100mg three times daily in terms of changes in the Ankle-Brachial Index (ABI).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Arterial Occlusive Diseases Intermittent Claudication

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sarpogrelate SR 300mg, QD

Group Type EXPERIMENTAL

Sarpogrelate SR

Intervention Type DRUG

Sarpogrelate SR 300mg, once a daily, for 24weeks

Sarpogrelate 100mg, TID

Group Type ACTIVE_COMPARATOR

Sarpogrelate

Intervention Type DRUG

Sarpogrelate 100mg, 3 times a day, for 24weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sarpogrelate SR

Sarpogrelate SR 300mg, once a daily, for 24weeks

Intervention Type DRUG

Sarpogrelate

Sarpogrelate 100mg, 3 times a day, for 24weeks

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Anplag SR Tab. 300mg Anplag Tab. 100mg

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female adults aged ≥ 19
* Diagnosis of chronic arterial occlusive disease
* Experience of intermittent claudication symptoms for at least 3 months
* Receiving Sarpogrelate for a minimum of 4 weeks prior to the baseline
* Lower limb pain measured at VAS 40mm or higher at baseline

Exclusion Criteria

* Patients with coronary artery disease or cerebrovascular disease related to arteriosclerosis undergoing or scheduled for surgery or medication treatment
* Patients with a history of severe heart failure within the 6 months prior to the screening
* Patients with a history of bleeding
* Patients receiving anticoagulants or medications with antiplatelet activity at baseline
* Patients diagnosed with peripheral neuropathy and currently taking neuropathic pain medications
* Patients with infectious or progressive fibrotic diseases such as rheumatoid arthritis, systemic lupus erythematosus, idiopathic pulmonary fibrosis, etc

Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No